VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PRMEPrime Medicine, Inc.
$3.23$583M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRMERevenue History

PRME logoPrime Medicine, Inc. (PRME) Revenue History

Annual and quarterly revenue from 2019 to present

TTM Revenue$4.0M▼ $598K vs FY2025
YoY Growth-41.1%Declining
Q1 2026$856K-41.1% YoY · +2.1% QoQ
Revenue CAGR
3Y—
→
5Y-2.3%
→
10Y—
Declining
Best Fiscal Year$5.2M (2020)
Best Quarter$2.2M (Q4 2024)
Revenue per Share$0.02
Revenue per Employee$19K

PRME Revenue Over Time (2019–2025)

PRME Revenue Growth History

1 of 2 years with positive growth
Annual Revenue Growth · Each cell = one fiscal year
2019—
2020—
2021-100.0%
2022—
2023—
2024—
2025+55.3%
FY2019 revenue growth
N/A
FY2020 revenue growth
N/A
FY2021 revenue growth
-100.0%
FY2022 revenue growth
N/A
FY2023 revenue growth
N/A
FY2024 revenue growth
N/A
FY2025 revenue growth
+55.3%
DeclineStrong growth
↑ 1-year growth streakBest: +55.3% (FY2025)Worst: -100.0% (FY2021)
Recent Quarterly Revenue & YoY Growth
QuarterRevenueYoY
Q1 2026$856K-41.1%
Q4 2025$838K-61.6%
Q3 2025$1.2M+486.1%
Q2 2025$1.1M—
Q1 2025$1.5M+146.0%
Q4 2024$2.2M—
Q3 2024$209K—
Q2 2024$0—
Seasonal Revenue Pattern (fiscal quarters)
Q1
26%
Q2
12%
Q3
17%
Q4
46%

Multi-year avg. share of annual revenue by fiscal quarter

Revenue Breakdown (FY 2025)

PRME's revenue distribution by segment and geography for fiscal year 2025

By Product/Segment

Reportable Segment100.0%

PRME Revenue Analysis (2019–2025)

Current Revenue & Growth

As of June 21, 2026, Prime Medicine, Inc. (PRME) generated trailing twelve-month (TTM) revenue of $4.0 million, reflecting significant decline in growth of -41.1% year-over-year. The most recent quarter (Q1 2026) recorded $856,000 in revenue, up 2.1% sequentially.

Historical Growth Trajectory

PRME's 5-year compound annual growth rate (CAGR) stands at -2.3%, indicating revenue contraction over this period. Prime Medicine, Inc.'s highest annual revenue of $5.2 million was recorded in 2020.

Revenue by Segment

PRME's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.

Peer Comparison

Compared to Healthcare sector peers — including BEAM (+108.0% YoY), CRSP (-88.9% YoY), and EDIT (+8.0% YoY) — PRME has underperformed the peer group in revenue growth. Compare PRME vs BEAM →

PRME Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
PRME logoPRMECurrent$4M-41.1%-2.3%-4498.1%
BEAM logoBEAM$140M+108.0%+466.3%-274.6%
CRSP logoCRSP$4M-88.9%+37.3%-16191.4%
EDIT logoEDIT$41M+8.0%-14.9%-245.2%
NTLA logoNTLA$68M+45.0%+3.1%-651.7%
KRRO logoKRRO$6M-20.3%-29.6%-1366.4%
Best in groupLowest in group

PRME Historical Revenue Data (2019–2025)

1–7 of 7 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$4.6M+55.3%$-2,689,000-58.1%$-208,350,000-4498.1%
2024$3.0M-$3.0M100.0%$-202,467,000-6787.4%
2023$0-$0-$-204,792,000-
2022$0-$0-$-116,544,000-
2021$0-100.0%$0-$-84,474,000-
2020$5.2M-$2.2M42.8%$-932,000-17.9%
2019$0-$-2,760,000-$-2,172,000-
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

7+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PRME — Frequently Asked Questions

Quick answers to the most common questions about buying PRME stock.

Is PRME's revenue growth accelerating or slowing?

PRME revenue is declining -41.1% year-over-year. TTM revenue fell to $4M, contrasting with the 5-year CAGR of -2.3%. The reversal reflects either macro headwinds or company-specific challenges.

What is PRME's revenue history from 2019 to 2026?

Prime Medicine, Inc. (PRME) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $4M, growing at -41.1% YoY. The 5-year CAGR is -2.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.

What is PRME's long-term revenue growth rate (CAGR)?

Prime Medicine, Inc.'s 5-year revenue CAGR of -2.3% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -41.1% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PRME.

Why does PRME's quarterly revenue fluctuate?

PRME quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Prime Medicine, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.

How is PRME's revenue distributed by segment?

PRME reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.

How does PRME's revenue compare to industry peers?

Prime Medicine, Inc. (PRME) with TTM revenue of $4M and -41.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.